1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
781 652 4500
https://www.avenuetx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 3
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Alexandra MacLean M.D. | CEO & Director | 413,2k | N/D | 1968 |
Mr. David Jin | Interim CFO, COO & Corporate Secretary | N/D | N/D | 1991 |
Dr. Lindsay Allan Rosenwald | Executive Director | N/D | N/D | 1955 |
Dr. Xiaoqin Lu M.D. | Consultant | 1,05M | N/D | 1975 |
Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer | 69,12k | N/D | 1947 |
Mr. Srinivas Subramanian | Executive Vice President | N/D | N/D | 1971 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
L'ISS Governance QualityScore di Avenue Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.